In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.
about
Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated CystitisAn update on the management of urinary tract infections in the era of antimicrobial resistance.Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.F33: A-: B-, IncHI2/ST3, and IncI1/ST71 plasmids drive the dissemination of fosA3 and bla CTX-M-55/-14/-65 in Escherichia coli from chickens in China.Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.Fosfomycin: An Alternative Therapy for the Treatment of UTI Amidst Escalating Antimicrobial Resistance.FosfomycinFosfomycin: Resurgence of an old companion.Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario.Escherichia coli sequence type 131: epidemiology and challenges in treatment.Glutathione-S-transferase FosA6 of Klebsiella pneumoniae origin conferring fosfomycin resistance in ESBL-producing Escherichia coli.Fosfomycin Susceptibility in Multidrug-Resistant Enterobacteriaceae Species and Vancomycin-Resistant Enterococci Urinary Isolates.Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli.Community-Acquired Urinary Tract Infection by in the Era of Antibiotic Resistance
P2860
Q26745740-ED0F9C9F-1C57-4E03-9FFE-C22E21E060D0Q30244815-AC3CA368-8069-4DDB-A229-B93A82748FD5Q33732529-B6EB5AFF-7C25-40F0-A5A4-2BFFF665A605Q34709726-5C111FA6-CBED-45A5-B4CF-A21173794D73Q36290521-775982E7-5F4C-4E60-967B-F2DC28D0CD3FQ36476574-B14D5060-D6BA-4CF1-A6DA-B410868C6105Q36675246-2D519505-A2ED-4FFF-BDFD-3C77CA75EDB3Q36803694-BEABA04A-A3E3-4522-AE9B-6CF9B0B77904Q37681591-947BFC75-16D6-4ECE-8DED-F6AAEC5A337AQ38201515-5D5D48A6-F756-406B-A70C-945F28B5D792Q40645840-A54D1532-965C-49E2-B084-41E351F6C9A3Q46267399-44740EAE-E3AC-47DF-9912-09814AB3B3DBQ48357061-C655F472-3392-4298-BE9D-43845BF62478Q53694305-526D8263-DDE1-482A-AB24-2ED3818C6DABQ57821217-7EDCF48D-7F40-4F48-927F-4638138F480F
P2860
In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In Vitro activity of fosfomyci ...... he CANWARD surveillance study.
@en
In Vitro activity of fosfomyci ...... he CANWARD surveillance study.
@nl
type
label
In Vitro activity of fosfomyci ...... he CANWARD surveillance study.
@en
In Vitro activity of fosfomyci ...... he CANWARD surveillance study.
@nl
prefLabel
In Vitro activity of fosfomyci ...... he CANWARD surveillance study.
@en
In Vitro activity of fosfomyci ...... he CANWARD surveillance study.
@nl
P2093
P2860
P356
P1476
In Vitro activity of fosfomyci ...... the CANWARD surveillance study
@en
P2093
Andrew J Denisuik
Daryl J Hoban
Heather J Adam
James A Karlowsky
Melanie R Baxter
P2860
P304
P356
10.1128/AAC.02399-13
P407
P577
2013-12-09T00:00:00Z